Fibrinolytic therapy for COVID-19: a review of case series.

Ji, Hong-Long; Dai, Yuling; Zhao, Runzhen

Ji, Hong-Long; Dai, Yuling; Zhao, Runzhen.

Ji HL; Department of Cellular and Molecular Biology, University of Texas at Tyler Health Science Center, Tyler, TX, USA. james.ji@uthct.edu.
Dai Y; Texas Lung Injury Institute, University of Texas at Tyler Health Science Center, Tyler, TX, USA. james.ji@uthct.edu.
Zhao R; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.

Acta Pharmacol Sin ; 43(8): 2168-2170, 2022 08.

Article in English | MEDLINE | ID: covidwho-1565710

Subject(s)

COVID-19 Drug Treatment; Fibrinolytic Agents/therapeutic use; Humans; Thrombolytic Therapy

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Limits: Humans Language: English Journal: Acta Pharmacol Sin Journal subject: Pharmacology Year: 2022 Document Type: Article Affiliation country: S41401-021-00827-w

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google